Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191080 | 0.85 | TSHR (0.41) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL1820951 | 0.83 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL28308139 | 0.82 | TSHR (0.49) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL4923093 | 0.80 | TSHR (0.51) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL10813783 | 0.79 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL2230167 | 0.77 | TDP1 (0.52) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL10411480 | 0.76 | SMN1; SMN2 (0.58) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL4924664 | 0.75 | SMN1; SMN2 (0.47) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 | |
| SCHEMBL9719276 | 0.75 | GPR35 (0.57) | TSHRALDH1A1TDP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4924130 | 0.75 | ALDH1A1 (0.45) | TSHRALDH1A1TDP1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227869-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof | MEN TEWA | 2008-09-18 | — | — | US | claimed |
| EP-1232748-B1 | USE OF SUBSTITUTED NITROBENZENE DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY BACTERIA, FUNGI AND VIRUSES | MEN TEWA (CN) | 2006-05-03 | — | — | EP | claimed |
| US-20050228055-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof | MEN TEWA | 2005-10-13 | — | — | US | claimed |
| CN-1679521-A | Use of substituting nitrobenzene derivative in products preparation | MEN TEWA (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1193746-C | Substituted nitrobenzene derivatives as pharmaceutical and other beneficial uses | NEN TEWA (CN) | 2005-03-23 | — | — | CN | claimed |
| EP-1232748-A1 | SUBSTITUTED NITROBENZENE DERIVATIVES AS MEDICINES AND OTHER USEFUL USES THEREOF | Men, Tewa (CN) | 2002-08-21 | — | — | EP | claimed |
| CN-1294911-A | Substituted nitrobenzene derivatives as pharmaceutical and other beneficial uses | MEN TEWA (CN) | 2001-05-16 | — | — | CN | claimed |
| US-20080227869-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof | MEN TEWA | 2008-09-18 | — | — | US | disclosed |
| EP-1232748-B1 | USE OF SUBSTITUTED NITROBENZENE DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY BACTERIA, FUNGI AND VIRUSES | MEN TEWA (CN) | 2006-05-03 | — | — | EP | disclosed |
| US-20050228055-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof | MEN TEWA | 2005-10-13 | — | — | US | disclosed |
| CN-1679521-A | Use of substituting nitrobenzene derivative in products preparation | MEN TEWA (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1193746-C | Substituted nitrobenzene derivatives as pharmaceutical and other beneficial uses | NEN TEWA (CN) | 2005-03-23 | — | — | CN | disclosed |
| EP-1232748-A1 | SUBSTITUTED NITROBENZENE DERIVATIVES AS MEDICINES AND OTHER USEFUL USES THEREOF | Men, Tewa (CN) | 2002-08-21 | — | — | EP | disclosed |
| CN-1294911-A | Substituted nitrobenzene derivatives as pharmaceutical and other beneficial uses | MEN TEWA (CN) | 2001-05-16 | — | — | CN | disclosed |
| CN-1049124-C | Artificial musk serial anti-inflammatory and anticancer compound Chinese patent medicine and making process thereof | BEIFANG MEDICINE DEVEL INST ZU (CN) | 2000-02-09 | — | — | CN | disclosed |
| EP-0497989-B1 | POLLUTION-FREE PROCESS FOR PRODUCING AROMATIC NITRO COMPOUND WITHOUT USING MINERAL ACID | NIPPON KAYAKU KK (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0497989-A1 | POLLUTION-FREE PROCESS FOR PRODUCING AROMATIC NITRO COMPOUND WITHOUT USING MINERAL ACID | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227869-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof | NOS3, NOS1, PTGS1 | TSHR 3651/4885ALDH1A1 571/4885TDP1 1154/4885 |
| US-20050228055-A1 | Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof | APOB, NDUFB1, CYP2F1 | TSHR 4369/4885ALDH1A1 700/4885TDP1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.